Phase 2 Endometrial Cancer Trial, Recruiting NCT05916196 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT05916196
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You have uterine cancer that has come back, spread to other parts of the body, or has not been treated with surgery, and this has been confirmed through a biopsy or standard medical scans (such as CT, PET/CT, MRI, bone scan, x-ray, or ultrasound)
  • You have at least one area of cancer detected by medical scans that is located somewhere other than the liver
  • You are willing to be told about the nature of the study, sign a consent form, and follow the study guidelines
  • If you are currently taking or have recently stopped taking tamoxifen, you must wait 8 weeks before having the study scan; if you recently stopped taking fulvestrant, you must wait 28 weeks before having the study scan

Who may not be able to join:

  • Women who are pregnant at the time of screening are not eligible; a urine pregnancy test will be done before the study injection for women who could potentially be pregnant
  • People who are unable to tolerate or go through the imaging procedures required for the study, as determined by a doctor
  • People who have any current medical condition, illness, or disorder that a doctor believes could put them at risk or prevent them from safely completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Neil Taunk, MD, Abramson CC

Phone: 2155736569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
5 April 2024
Est. completion
1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

rate of FES positivity in ER+ uterine cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov